Emergent BioSolutions | EBS - Zysk Z Działalności Operacyjnej





Zysk Z Działalności Operacyjnej Zmiana Data
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Emergent BioSolutions USD -218M 69.9M 2023-06
Exelixis USD 235.91M 20.45M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Lonza CHF 673M 243M 2025-06
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Myriad Genetics USD -3M 20.3M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Xoma USD -15.64M 5.56M 2024-09